直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

USPTO Issues Guidance on the Treatment of Applicant Admitted Prior Art During Inter Partes Review

August 24, 2020

Authored and Edited by Richard Hildreth; Safiya Aguilar; Jason E. Stach

On August 18, 2020, the U.S. Patent Office published a guidance memorandum regarding the treatment of applicant statements in a patent challenged in an IPR (“applicant admitted prior art” or “AAPA”). The PTO observed that different Board panels had reached inconsistent interpretations as to whether and how 35 U.S.C. § 311(b) limits an IPR petitioner's reliance on those statements.

35 U.S.C. § 311(b) provides that an IPR challenge may be based “only on the basis of prior art consisting of patents or printed publications.” Noting that a “patent cannot be prior art to itself,” the PTO explained that applicant statements in the challenged patent do not qualify as a patent or printed publication and therefore are not prior art under § 311(b). However, it stated that AAPA does fall into the category of evidence the Board may consider for more limited purposes, such as providing evidence of the general knowledge possessed by someone of ordinary skill in the art or to support a motivation to combine.

The PTO instructed Board panels to examine whether the petitioner uses the specification statements, in conjunction with at least one prior-art patent or publication, as evidence of the general knowledge of a person of ordinary skill in the art. The PTO further clarified that the intent of § 311(b) is not to foreclose considering pertinent evidence of patentability, but to ensure that at least one prior-art patent or publication forms the basis of the IPR. This interpretation, as asserted by the PTO, is consistent with other AIA provisions, including 35 U.S.C. §§ 312, 314, and 316.

Accordingly, petitioners may use AAPA to evidence the level of skill in the art and to support arguments regarding the motivation to combine prior art references. In some circumstances, petitioners may also rely on AAPA to establish that a missing claim limitation was generally known in the art before the challenged patent’s filing date. As with other types of supporting evidence, patentees are free to challenge the accuracy of a petitioner’s characterization of the AAPA, and the Board retains discretion to assess whether the AAPA constitutes evidence of general knowledge of the art.

Although it remains to be seen whether application of this guidance is reviewable by the Federal Circuit—and if so, whether the Federal Circuit will agree with the PTO’s interpretation of § 311(b)—the guidance is binding on the Board for the time being.

Tags

America Invents Act (AIA), Patent Trial and Appeal Board (PTAB), prior art

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Atlanta, GA

Washington, DC

Contacts

Safiya Aguilar
Associate
Washington, DC
+1 202 408 4160
Email
Jason E. Stach
Partner
Atlanta, GA
+1 404 653 6428
Email

Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP